Drug Profile
Research programme: macrocycle drugs - Spexis/Taisho
Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Polyphor; Taisho Pharmaceutical
- Developer Spexis; Taisho Pharmaceutical
- Class Macrocyclic compounds
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Unspecified in Switzerland
- 17 Sep 2015 Polyphor and Taisho enter into research collaboration for the development of macrocycle drugs
- 17 Sep 2015 Early research in Undefined indication in Switzerland (unspecified route)